AI Summary
At EHA 2026, Lilly will present BRUIN CLL-322 results showing time-limited pirtobrutinib plus venetoclax/rituximab improves PFS versus venetoclax/rituximab alone. The company also notes data from Ajax and Kelonia as it advances its hematology strategy through pending acquisitions; success hinges on closing, regulatory milestones, and subsequent clinical readouts.
Sentiment Rationale
Key Phase 3 BRUIN CLL-322 anecdotally outperformed control, signaling peak-blend potential for Jaypirca in combination regimens; acquisitions of Ajax/Kelonia add optionality and near-term pipeline upside; expected closings in 2026 increase visibility, though execution timing risks exist.
Trading Thesis
Positive BRUIN CLL-322 data and acquisitions could lift LLY stock in 2H 2026.
Market-Moving
- BRUIN CLL-322 readout may drive near-term sentiment on Lilly's hematology portfolio.
- Ajax and Kelonia deal closings could expand pipeline visibility and valuation.
- EHA data releases in mid-June may trigger intraday volatility around presentations.
- BTK/non-covalent inhibitors safety/tolerability data remain a key risk.
Key Facts
- BRUIN CLL-322: time-limited pirtobrutinib plus venetoclax/rituximab improves PFS.
- Lilly to acquire Ajax Therapeutics and Kelonia Therapeutics; acquisitions pending.
- Ajax to present AJX-101 Phase 1 data for a type II JAK2 inhibitor in myelofibrosis.
- Kelonia to present KLN-1010 in vivo CAR-T data in RRMM; correlative findings.
- EHA meeting June 11-14, 2026 in Stockholm; Lilly to spotlight hematology portfolio.
Companies Mentioned
- Eli Lilly and Company (LLY): Leading hematology strategy; data drives stock if pipeline momentum and acquisitions close.
- Ajax Therapeutics, Inc. (AJX): AJX-101 Phase 1 data to be showcased; potential strategic asset for Lilly post-acquisition.
- Kelonia Therapeutics, Inc. (KLN): KLN-1010 in vivo CAR-T data to be presented; supports Lilly's CAR-T/BCMA efforts.
Corporate Developments
Category: Corporate Developments. It combines clinical readouts with strategic M&A activity, shaping Lilly's hematology growth trajectory.